If Wall Street has taught investors anything, it’s that the market is finicky. There is no way to know what the future holds, but there are some things you can do. “sure thing”When it comes to investing, analysts agree with biotech companies as a solid opportunity.
One company that stands out above its peers is Endonovo Therapeutics (ENDV)Biotechnology company that develops bioelectronics-based products for regenerative medicine.
Analysts believe that the company’s focus on both medical devices and cell therapies is what makes it so appealing.
Endonovo’s devices are based upon the Time-Varying Electromagnetic Field technology, which was originally developed by NASA. The technology works by sending electromagnetic pulses that deliver electrical stimulation to cells and the nervous system. These devices are not invasive and non-implantable. They are used to prevent and treat critical organ failure.
Endonovo’s technology has been proven to be innovative in treating acute inflammation. This is unlike other treatments that use implantable electrodes. The company is currently focusing its efforts on liver inflammation, which, if validated could transform medicine as inflammation is the root cause of all diseases.
The company also plans to apply for an orphan drug designation for its next generation, off-the shelf treatment for Graft-Versus Host (GvHD), using enhanced stem cells taken from the human umbilical chord.
Endonovo could easily achieve a billion dollars if it receives FDA approval for its product.
GvHD is a rare condition where immune cells from donor bone marrow and cord blood transplants attack the recipient, leading to a failure of the transplant. This causes significant morbidity and death among recipients.
Endonovo is unique among other companies looking to treat GvHD. Endonovo does not use genetic modification or small-molecule drugs to improve stem cell therapeutic properties. Yahoo Finance reports that ENDV may be able to adapt its approach to other types and can be scaled up to make them.
Visit this site for more information www.endonovo.com.
